Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy

19Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

All men and most women with X-linked adrenoleukodystrophy (ALD) develop myelopathy in adulthood. As clinical trials with new potential disease-modifying therapies are emerging, sensitive outcome measures for quantifying myelopathy are needed. This prospective cohort study evaluated spinal cord size (cross-sectional area - CSA) and shape (eccentricity) as potential new quantitative outcome measures for myelopathy in ALD. Seventy-four baseline magnetic resonance imaging (MRI) scans, acquired in 42 male ALD patients and 32 age-matched healthy controls, and 26 follow-up scans of ALD patients were included in the study. We used routine T1-weighted MRI sequences to measure mean CSA, eccentricity, right-left and anteroposterior diameters in the cervical spinal cord. We compared MRI measurements between groups and correlated CSA with clinical outcome measures of disease severity. Longitudinally, we compared MRI measurements between baseline and 1-year follow-up. CSA was significantly smaller in patients compared to controls on all measured spinal cord levels (P

Cite

CITATION STYLE

APA

van de Stadt, S. I. W., van Ballegoij, W. J. C., Labounek, R., Huffnagel, I. C., Kemp, S., Nestrasil, I., & Engelen, M. (2020). Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy. Journal of Inherited Metabolic Disease, 43(4), 852–860. https://doi.org/10.1002/jimd.12226

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free